This site is intended for health professionals only

Published on 1 October 2009

Share this story:

Superior efficacy-dose ratio for Lantus over detemir


A study carried out shows the benefits of once-daily, 24-hour basal insulin Lantus when compared to twice-daily insulin detemir.

Sanofi-aventis announced results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin detemir.

The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, patients taking Lantus required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7% without symptomatic hypoglycaemia compared to patients on insulin detemir, who received 76.5 units – an increase of 76%.

Despite lower doses of insulin in the glargine group, Lantus once-daily and insulin detemir twice-daily resulted in similar improvements in glycemic control (HbA1c) and a similar risk of hypoglycaemia. Patients in the Lantus arm of the study also achieved significantly lower fasting blood glucose.

In the study, patients taking Lantus once-daily reported a significantly greater treatment satisfaction over insulin detemir twice-daily, with over 50% less drop-outs. Whilst a similar rate of overall hypoglycaemia and nocturnal hypoglycaemia was observed in both arms, patients on Lantus once-daily experienced less daytime hypoglycaemia as compared to insulin detemir. Patients on insulin detemir experienced less weight gain.

To find out more, please click on the link below.


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: